global stocks
We reran the R&D efficiency screen across 10 exchanges with local benchmarks. UK beats FTSE 100 (price return) by +7.22% annually — the strongest result globally. India, previously the standout vs SPY, now underperforms the Sensex by 4.65pp. Local benchmarks change everything. Pharma-heavy...
india stocks
The R&D efficiency screen on NSE-only sits in cash for 56% of years. When invested (2014-2024), it produced volatile results with two spectacular years (2014 +58% vs Sensex, 2023 +91% vs Sensex). But the 25-year CAGR of 7.41% trails the Sensex''s 12.06%. The screen finds India''s best pharma and...
uk stocks
The UK R&D efficiency screen returned 8.45% CAGR over 25 years. The FTSE 100 price index returned 1.23%. That is +7.22% annual excess, the strongest result across 10 global markets. Max drawdown was -17.26%. Returns in GBP. Benchmark caveat: FTSE 100 is price-return only.
r&d
From 2000 to 2012, buying stocks with the highest gross profit per R&D dollar beat the S&P 500 consistently. Then mega-cap tech took over, and the strategy spent the next twelve years giving money back. 25-year backtest, full data, SQL included.